Alamar Biosciences to Participate in Upcoming Investor Conferences
Alamar Biosciences (Nasdaq: ALMR) will participate in the UBS Global Healthcare Conference and Citi’s 2026 Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alamar Biosciences (Nasdaq: ALMR) will participate in the UBS Global Healthcare Conference and Citi’s 2026 Global Healthcare Conference.
The UBS fireside chat in Palm Beach Gardens, Florida, is November 10 at 2:00 p.m. Pacific / 5:00 p.m. Eastern. Citi investor meetings in Miami, Florida, are December 2. A live and archived session webcast will be available at investors.alamarbio.com.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fremont, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be participating in the following investor conferences:
- UBS Global Healthcare Conference in Palm Beach Gardens, FL
Fireside chat on Tuesday, November 10 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time
- Citi’s 2026 Global Healthcare Conference in Miami, FL
Investor meetings on Wednesday, December 2
Interested parties may access a live and archived webcast of the session on the “Investors” section of the company website at investors.alamarbio.com.
About Alamar Biosciences, Inc.
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO® HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com.
Media Contact Alamar Biosciences, Inc. media@alamarbio.com Investor Contact Alamar Biosciences, Inc.